A locally administered single-cycle #influenza #vaccine expressing a non-fusogenic stabilized #hemagglutinin stimulates strong T-cell and neutralizing #antibody #immunity
ABSTRACT Current influenza vaccination approaches protect against specific viral strains, but do not consistently induce broad and long-lasting protection to the diversity of circulating influenza viruses. Single-cycle viruses delivered to the respiratory tract may offer a promising solution as they safely express a diverse array of viral antigens by undergoing just one round of cell infection in their host and stimulate broadly protective resident memory T-cell responses in the lung. We have previously developed a vaccine candidate called S-FLU , which is limited to a single cycle of infection by inactivation of the hemagglutinin signal sequence and induces a broadly cross-reactive T-cell response and antibodies to neuraminidase, but fails to induce neutralizing antibodies to hemagglutinin after intranasal administration. This study describes the development of CLEARFLU , a derivative of S-FLU, which is designed to add a neutralizing antibody response to hemagglutinin. In contrast to ...